A state health department is reviewing research to get insight into whether kratom and marijuana can treat chronic pain with minimal side effects.
AHRQ (Agency for Healthcare Research and Quality) is requesting the public to assist in finding studies related to the merits and risks of cannabis and kratom. The latter is a plant recognized for its analgesic properties.
The public has up to 4th January next year to submit data on how kratom and cannabinoids affect chronic pain.
AHRQ asserted in a notice that some studies indicate that cannabinoids may contain analgesic effects but research in this niche is mixed. It added that THC has shown analgesic abilities but the abuse potential and psychoactive effects boost its suitability and risk as an analgesic.
The agency went on to say that other cannabis elements such as CBC, CBG and CBD may also contain anti-inflammatory or analgesic properties and are not labelled as addictive or psychoactive, however they might not be potent like THC.
The state agency further disclosed the impact of cannabis prohibition and the prospective perks of federal-level authorization. It also said that although some plant-based compounds (PBCs) believed to minimize pain are presently categorized as Schedule I by the DEA ( Drugs Enforcement Agency), the recent marijuana legalization by a plethora of states may culminate in more cannabis research and higher quality.
The four major questions AHRQ hopes to answer in its strategic review include:
- In adults suffering from severe pain, what perks do cannabinoids offer?
- In adults suffering from adverse pain, what side-effects are associated with cannabinoids?
- In adults suffering from chronic pain, what merits do Kratom or other PBCs for chronic pain treatment offer?
- In adults suffering from severe pain, what side-effects are associated with kratom and other PBCs for chronic pain treatment?